Henan Zhoukou: Xiangcheng Julin Building Biomedical Strategic Emerging Industry

Zhoukou Daily · Zhou Dao client reporter Zhang Zhixin text/picture

Yesterday, the summer heat was flourishing. The LE Pharmaceutical Production Workshop in Xiangkou City, Henan Province was cool. Workers were wearing work clothes and were working meticulously on the modern assembly line (pictured).

As the head geese enterprise of Zhoukou's biomedical industry, Lepu Pharmaceutical achieved sales revenue of 1.3 billion yuan in 2021 and 230 million yuan in profits and taxes.

In May of this year, Xiang City's "two sessions" proposed that the biomedical industry base will be built, the provincial biomedical industry cluster will be cultivated. High -end raw material projects with 100 million yuan, relying on the Provincial Enterprise Technology Center of Lepu Pharmaceuticals and the Provincial Engineering Research Center of Kangda Pharmaceuticals to build a biomedical research and development and production center.

Practice is the most powerful proof. On July 5th, the fifth phase of the "three batches" key projects of Zhoukou City was held. On this day, the Xiangcheng City LEP Da Health Industrial Park project with a total investment of 1.35 billion yuan started at the same time. It is planned to build a new drug research and development center and sterile biological agent, medical beauty products, medical device intelligent production and other workshops. It is reported that of the four "three batches" key projects signed on the day of Xiangcheng, there are two pharmaceutical projects, namely the Kangda High -end raw materials and drug production projects and Lepu high -end medical products and medical device production projects. It further consolidated the solid position of the biomedical industry in Xiangcheng as the leading industry.

In recent years, the Xiangcheng Municipal Party Committee and the Municipal Government focused on the leading industry of biomedical, adhered to high grafting, adhered to advantages and reconstruction, adhered to the environmental improvement, adhered to the "project as king", exerted comparative advantages, stimulated internal potential, extend chain to replenish chain, biological biology, biological creatures The strong rise of the pharmaceutical industry has become a powerful engine for the high -quality development of the city industry.

The biomedical industry is called "never decaying rising industry." Especially since the epidemic of new coronary pneumonia, the biomedical industry has attracted much attention and has become one of the world's new round of scientific and technological revolution and national strength competition.

For a long time, the biopharmaceutical industry is the advantageous industry of Xiangcheng, with a good development foundation, more pharmaceutical approval scholarship resources, and the country's environment that encourages the development of the biomedical industry. After various investigations and scientific demonstrations, the Xiangcheng Municipal Party Committee and Municipal Government determined that the biopharmaceutical industry was positioned as the positioning of the development of the leading industry, and it brightened this most industrial characteristics, the most comparative advantage, and the most competitive industrial business card.

In this regard, the Xiangcheng Municipal Party Committee and the Municipal Government have formulated the "Special Plan for the Development of the Biomedical Industry" and issued documents such as the "Implementation Opinions on Accelerating the Development and Growth of the Biomedical Industry" and "Promotional Policy on Investment Promotional Policy for Investment in the Biomedical Industry", focusing on clear biomedicine The strategic positioning and development measures of industrial development, the high starting point clearly clear the development plan and goals of the "14th Five -Year Plan" biomedical industry. Based on Lepu Pharmaceutical and Kangda Pharmaceutical, planning and building a city biomedical industry park in the project, striving for "14th Five -Year Plan "At the end, the biomedical industry cluster with an output value of 15 billion yuan promoted the development of high -end, large -scale, and clusterization to the biomedical industry.

Faced with the situation of extensive management of the biomedical industry, unclear property rights, incomplete mechanisms, and insufficient R & D investment, the Xiangcheng Municipal Party Committee and Municipal Government set up the leadership group of the reform of the biomedical industry system. Implement the strategic restructuring and reorganization of pharmaceutical companies, and rely on "reborn and bones" to achieve "strong muscles and strong bones."

Nowadays, Xiangcheng is based on the development of the biomedical industry, promotes high levels, clarifys ideas, relying on strong attracting strong, leading leaders, Lepu Pharmaceutical, Kangda Pharmaceutical, Liuhetang Pharmaceutical and other batch of independent intellectual property rights and main business are prominent. The large companies and large groups with strong core competitiveness stand out.

Innovation is the first productive forces. In order to continuously improve the innovation capabilities and core competitiveness of the biomedical industry, Xiangcheng adheres to the goal of transformation, quality improvement, and innovation, focusing on new technologies, new formats, and new models, with "three major transformations" as the starting point, focusing on attracting investment and quotation The combination of wisdom, the combination of industrial upgrading and scientific and technological research and development, the unification of independent research and development and research institutes, has effectively promoted the enterprise scientific and technological innovation and product innovation, and the core competitiveness of the enterprise has been greatly improved.

In this regard, Lepu Pharmaceuticals has introduced the world's advanced technology, equipment and processes in accordance with the intelligent and green standards, and accelerated the production and operation of the annual output of 3 billion tablets and 20 million frozen dry powder injections. Improve the intelligent and refined and refined production of enterprises in production and development and management, realize the digitalization of drug quality control and testing, increase the test cycle and risk recognition level by 16%, comprehensive energy consumption decreases by 20%, and obtain significant social and economic benefits. Kangda Pharmaceutical is the largest sterile raw material production base in Henan Province. This year, it has invested in implementing the upgrade and reconstruction of sterile raw materials. After the project is completed, it will enter the first -class square matrix of the national aseptic raw materials.

Project construction is an important engine to promote the high -quality development of the biomedical industry. For the concept of "the project is king, the investment promotion is the main, it is planned to be first, and the landing is the big" concept, Xiangcheng aims at domestic and foreign pharmaceutical head companies to attract strong and actively connect with enterprises such as central enterprises and leading enterprises in the pharmaceutical industry. Strong pharmaceutical production projects promote the development of the biomedical industry chain and cluster development.

Since the beginning of this year, five medical projects of Tianjin Hongri Pharmaceutical Chinese Medicine Granules, Hangzhou Shijia Medical Devices Production, Shanghai Emerging Biological, China Resources Shuanghe Pharmaceuticals, and Shanghai Remiece Biomedical Intermediate are actively connected. Relying on Beijing Leipu Headquarters and Yuekang Group Headquarters, the establishment of a professional investment group with the leaders of Xiangcheng as the leader of the group, strengthening top -level design, revitalizing existing assets, new high -quality projects, and building a biomedical research and development and production center. This year, Lepu Pharmaceuticals invested in the construction of a production line of 100 million bags of creamplasia cream, an annual output of 100 million diagnostic reagent production lines, further extend the chain to replenish the chain, cultivate new profit growth points, and enhance the core competitiveness of the enterprise. Kangda Pharmaceutical's new Kangda Phase II expanded high -end raw material drug projects, realized 1,400 tons of annual product -produced raw materials, and created the country's largest cephalosporin sterile -based raw material drug production base. Next, the Xiangcheng Municipal Party Committee and Municipal Government will take the biomedical industry as the cultivation and development of the strategic emerging industries, focus on the biomedical industry chain, adhere to cluster development and chain development, and prepare the industrial chain, enterprise chain, product chain, and R & D institutions " Four pictures ", a new batch of new projects with large investment volume, good comprehensive benefits, and a lot of taxation contributions, new projects, and good projects to achieve parkization and scale. At present, Xiangcheng is planning to build a biomedical industrial park and sewage treatment plant, public laboratories, logistics and other public supporting facilities to build a gathering of biomedical industries and specialized parks, promote the high -quality development of the biomedical industry, and move towards the mid -to -high -end level. Essence

It is understood that as of now, there are 5 biomedical enterprises above designated size in Xiangcheng, 276 national and western medicine approval documents, 11 national three types of new medicines, 3 Chinese medicine protection varieties, 3 exclusive varieties, 9 national patented products 9 One, 1 new category of new categories and 6 new drugs in the national second category, and 8 new national drug products have been approved. The main products involve more than a dozen dosage forms such as powder injections, water injections, tablets, capsules, particles, and wine agents. It covers 278 varieties of 278 varieties, 278 varieties, including biopharmaceuticals, biopharmaceuticals, chemicals, Chinese medicines, and health products. Specifications for chemical products. The biomedical industry cluster is identified by the Provincial Department of Industry and Information Technology as "the characteristic industrial cluster of Small and medium -sized enterprises in Henan Province".

- END -